Roche Holding AG Price to Sales Ratio 2010-2024 | RHHBY
Historical PS ratio values for Roche Holding AG (RHHBY) over the last 10 years. The current P/S ratio for Roche Holding AG as of July 08, 2025 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Roche Holding AG P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2025-07-07 |
40.31 |
|
0.00 |
| 2024-12-31 |
33.76 |
0 |
0.00 |
| 2024-06-30 |
33.55 |
0 |
0.00 |
| 2023-12-31 |
33.64 |
0 |
0.00 |
| 2023-06-30 |
35.47 |
0 |
0.00 |
| 2022-12-31 |
35.05 |
0 |
0.00 |
| 2022-06-30 |
37.34 |
0 |
0.00 |
| 2021-12-31 |
45.05 |
0 |
0.00 |
| 2021-06-30 |
40.96 |
0 |
0.00 |
| 2020-12-31 |
37.06 |
0 |
0.00 |
| 2020-06-30 |
36.67 |
0 |
0.00 |
| 2019-12-31 |
33.32 |
0 |
0.00 |
| 2019-06-30 |
28.77 |
0 |
0.00 |
| 2018-12-31 |
24.67 |
0 |
0.00 |
| 2018-06-30 |
21.93 |
0 |
0.00 |
| 2017-12-31 |
24.15 |
0 |
0.00 |
| 2017-06-30 |
24.32 |
0 |
0.00 |
| 2016-12-31 |
21.13 |
0 |
0.00 |
| 2016-06-30 |
24.41 |
0 |
0.00 |
| 2015-12-31 |
24.72 |
0 |
0.00 |
| 2015-06-30 |
25.15 |
0 |
0.00 |
| 2014-12-31 |
23.61 |
0 |
0.00 |
| 2014-06-30 |
25.91 |
0 |
0.00 |
| 2013-12-31 |
23.66 |
0 |
0.00 |
| 2013-06-30 |
20.85 |
0 |
0.00 |
| 2012-12-31 |
16.42 |
0 |
0.00 |
| 2012-06-30 |
14.06 |
0 |
0.00 |
| 2011-12-31 |
13.25 |
0 |
0.00 |
| 2011-06-30 |
13.07 |
0 |
0.00 |
| 2010-12-31 |
10.89 |
0 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$257.158B |
$68.726B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
